Cationic lipid and polymer-based gene delivery to human pacreatic islets

Ram I. Mahato, James Henry, Ajit S. Narang, Omaima Sabek, Daniel Fraga, Malak Kotb, Omma Gaber

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Transplantation of pancreatic islets has great potential for treating Type I diabetes. Ex vivo gene therapy may promote re-vascularization or inhibit apoptosis of the islets and promote graft. In this study, we investigated the feasibility of non-viral gene delivery using Enhanced Green Fluorescent Protein (EGFP) and human Vascular Endothelial Growth Factor (hVEGF165) expression plasmids as model reporter and therapeutic genes. LipofectAMINE/pDNA and Superfect/pDNA complexes showed high transfection efficiency in rapidly dividing Jurkat cells, but low transfection in non-dividing human islets. LipofectAMINE/pCAGGS-hVEGF transfected islets showed relatively higher levels of hVEGF than in those transfected with LipofectAMINE/pCMS-EGFP complexes or 5% glucose. To exclude endogenously secreted hVEGF, real time RT-PCR experiment was repeated using pCAGGS vector-specific forward primer and hVEGF gene-specific reverse primer. In this case, both non-transfected islets and the islets transfected with LipofectAMINE/pCMS-EGFP complexes showed negligible amplification of hVEGF. On glucose challenge, insulin release from LipofectAMINE/pCAGGS-hVEGF transfected human islets increased from 10.78 ± 4.56 to 65 ± 5 ng/ml, suggesting little adverse effect on islet β cell response to glucose challenge. The low transfection efficiency is due to the islets being a cluster of approximately 1000 non-dividing cells. This underscores the importance of experimentation with the actual human islets.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalMolecular Therapy
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Polymers
Lipids
Transfection
Genes
Glucose
Islets of Langerhans Transplantation
Jurkat Cells
Type 1 Diabetes Mellitus
Islets of Langerhans
Reporter Genes
Genetic Therapy
Real-Time Polymerase Chain Reaction
Plasmids
Lipofectamine
Insulin
Apoptosis
Transplants
enhanced green fluorescent protein
Therapeutics

Keywords

  • Cationic liposomes
  • Green fluorescent protein
  • HVEGF
  • Human islets
  • Insulin secrection
  • Polymer
  • Real time RT-PCR
  • Transfection

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Mahato, R. I., Henry, J., Narang, A. S., Sabek, O., Fraga, D., Kotb, M., & Gaber, O. (2003). Cationic lipid and polymer-based gene delivery to human pacreatic islets. Molecular Therapy, 7(1), 89-100. https://doi.org/10.1016/S1525-0016(02)00031-X

Cationic lipid and polymer-based gene delivery to human pacreatic islets. / Mahato, Ram I.; Henry, James; Narang, Ajit S.; Sabek, Omaima; Fraga, Daniel; Kotb, Malak; Gaber, Omma.

In: Molecular Therapy, Vol. 7, No. 1, 01.01.2003, p. 89-100.

Research output: Contribution to journalArticle

Mahato, RI, Henry, J, Narang, AS, Sabek, O, Fraga, D, Kotb, M & Gaber, O 2003, 'Cationic lipid and polymer-based gene delivery to human pacreatic islets', Molecular Therapy, vol. 7, no. 1, pp. 89-100. https://doi.org/10.1016/S1525-0016(02)00031-X
Mahato, Ram I. ; Henry, James ; Narang, Ajit S. ; Sabek, Omaima ; Fraga, Daniel ; Kotb, Malak ; Gaber, Omma. / Cationic lipid and polymer-based gene delivery to human pacreatic islets. In: Molecular Therapy. 2003 ; Vol. 7, No. 1. pp. 89-100.
@article{71b87122591948b3b4414d80e97a2926,
title = "Cationic lipid and polymer-based gene delivery to human pacreatic islets",
abstract = "Transplantation of pancreatic islets has great potential for treating Type I diabetes. Ex vivo gene therapy may promote re-vascularization or inhibit apoptosis of the islets and promote graft. In this study, we investigated the feasibility of non-viral gene delivery using Enhanced Green Fluorescent Protein (EGFP) and human Vascular Endothelial Growth Factor (hVEGF165) expression plasmids as model reporter and therapeutic genes. LipofectAMINE/pDNA and Superfect/pDNA complexes showed high transfection efficiency in rapidly dividing Jurkat cells, but low transfection in non-dividing human islets. LipofectAMINE/pCAGGS-hVEGF transfected islets showed relatively higher levels of hVEGF than in those transfected with LipofectAMINE/pCMS-EGFP complexes or 5{\%} glucose. To exclude endogenously secreted hVEGF, real time RT-PCR experiment was repeated using pCAGGS vector-specific forward primer and hVEGF gene-specific reverse primer. In this case, both non-transfected islets and the islets transfected with LipofectAMINE/pCMS-EGFP complexes showed negligible amplification of hVEGF. On glucose challenge, insulin release from LipofectAMINE/pCAGGS-hVEGF transfected human islets increased from 10.78 ± 4.56 to 65 ± 5 ng/ml, suggesting little adverse effect on islet β cell response to glucose challenge. The low transfection efficiency is due to the islets being a cluster of approximately 1000 non-dividing cells. This underscores the importance of experimentation with the actual human islets.",
keywords = "Cationic liposomes, Green fluorescent protein, HVEGF, Human islets, Insulin secrection, Polymer, Real time RT-PCR, Transfection",
author = "Mahato, {Ram I.} and James Henry and Narang, {Ajit S.} and Omaima Sabek and Daniel Fraga and Malak Kotb and Omma Gaber",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1525-0016(02)00031-X",
language = "English (US)",
volume = "7",
pages = "89--100",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cationic lipid and polymer-based gene delivery to human pacreatic islets

AU - Mahato, Ram I.

AU - Henry, James

AU - Narang, Ajit S.

AU - Sabek, Omaima

AU - Fraga, Daniel

AU - Kotb, Malak

AU - Gaber, Omma

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Transplantation of pancreatic islets has great potential for treating Type I diabetes. Ex vivo gene therapy may promote re-vascularization or inhibit apoptosis of the islets and promote graft. In this study, we investigated the feasibility of non-viral gene delivery using Enhanced Green Fluorescent Protein (EGFP) and human Vascular Endothelial Growth Factor (hVEGF165) expression plasmids as model reporter and therapeutic genes. LipofectAMINE/pDNA and Superfect/pDNA complexes showed high transfection efficiency in rapidly dividing Jurkat cells, but low transfection in non-dividing human islets. LipofectAMINE/pCAGGS-hVEGF transfected islets showed relatively higher levels of hVEGF than in those transfected with LipofectAMINE/pCMS-EGFP complexes or 5% glucose. To exclude endogenously secreted hVEGF, real time RT-PCR experiment was repeated using pCAGGS vector-specific forward primer and hVEGF gene-specific reverse primer. In this case, both non-transfected islets and the islets transfected with LipofectAMINE/pCMS-EGFP complexes showed negligible amplification of hVEGF. On glucose challenge, insulin release from LipofectAMINE/pCAGGS-hVEGF transfected human islets increased from 10.78 ± 4.56 to 65 ± 5 ng/ml, suggesting little adverse effect on islet β cell response to glucose challenge. The low transfection efficiency is due to the islets being a cluster of approximately 1000 non-dividing cells. This underscores the importance of experimentation with the actual human islets.

AB - Transplantation of pancreatic islets has great potential for treating Type I diabetes. Ex vivo gene therapy may promote re-vascularization or inhibit apoptosis of the islets and promote graft. In this study, we investigated the feasibility of non-viral gene delivery using Enhanced Green Fluorescent Protein (EGFP) and human Vascular Endothelial Growth Factor (hVEGF165) expression plasmids as model reporter and therapeutic genes. LipofectAMINE/pDNA and Superfect/pDNA complexes showed high transfection efficiency in rapidly dividing Jurkat cells, but low transfection in non-dividing human islets. LipofectAMINE/pCAGGS-hVEGF transfected islets showed relatively higher levels of hVEGF than in those transfected with LipofectAMINE/pCMS-EGFP complexes or 5% glucose. To exclude endogenously secreted hVEGF, real time RT-PCR experiment was repeated using pCAGGS vector-specific forward primer and hVEGF gene-specific reverse primer. In this case, both non-transfected islets and the islets transfected with LipofectAMINE/pCMS-EGFP complexes showed negligible amplification of hVEGF. On glucose challenge, insulin release from LipofectAMINE/pCAGGS-hVEGF transfected human islets increased from 10.78 ± 4.56 to 65 ± 5 ng/ml, suggesting little adverse effect on islet β cell response to glucose challenge. The low transfection efficiency is due to the islets being a cluster of approximately 1000 non-dividing cells. This underscores the importance of experimentation with the actual human islets.

KW - Cationic liposomes

KW - Green fluorescent protein

KW - HVEGF

KW - Human islets

KW - Insulin secrection

KW - Polymer

KW - Real time RT-PCR

KW - Transfection

UR - http://www.scopus.com/inward/record.url?scp=0037221558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037221558&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(02)00031-X

DO - 10.1016/S1525-0016(02)00031-X

M3 - Article

C2 - 12573622

AN - SCOPUS:0037221558

VL - 7

SP - 89

EP - 100

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -